The benefits of fingolimod in multiple sclerosis patients experiencing persistent disease activity despite previous treatment with disease-modifying therapies: results from the phase III TRANSFORMS study and its extension: P901


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles